Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: A meta-analysis of randomized trials

Overview

cited authors

Huang, Qingyuan; Zhang, Hua; Hai, Josephine; Socinski, Mark A.; Lim, Eric; Chen, Haiquan; Stebbing, Justin

authors

Socinski, Mark A., MD

Publication Date

December 2, 2018

webpage

Web of Science

published in

ONCOIMMUNOLOGY Journal

Research

keywords

anti-PD-1
atezolizumab
immunotherapy
nivolumab
non-small cell lung cancer
pembrolizumab

301 E Princeton St., Orlando, FL 32804 | FH.RAS@AdventHealth.com | 407-200-2901

The information on this website is not a substitute for examination, diagnosis, and medical care provided by a licensed and qualified health professional. Please consult your physician before undertaking any form of medical treatment and/or adopting any exercise program or dietary guidelines. If you think you may have a medical emergency, call your physician or 911 immediately. AdventHealth Research Institute reserves the right to add, remove or edit content on this page at its sole discretion.